Do Options Traders Know Something About Harrow Stock We Don't?
Investors need to pay close attention to HROW stock based on the movements in the options market lately.
HROW - Harrow Health, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$66.50
DETAILS
HIGH:
$88.00
LOW:
$45.00
MEDIAN:
$66.50
CONSENSUS:
$66.50
UPSIDE:
136.91%
Stock News
Harrow (NASDAQ:HROW) Stock Keeps Buy Rating at BTIG Research
Harrow (NASDAQ: HROW - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $63.00 target price on the stock. BTIG Research's price objective indicates a potential upside of 106.19% from the company's current price. Several
Harrow Closes Acquisition of TYRVAYA®
First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise
Harrow, Inc. (NASDAQ:HROW) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages
Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings: American Academy of Optometry's (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim, California; and American Academy of Ophthalmology's (AAO) Annual Meeting, taking place October 9–12, 2026, in New Orleans, Louisiana.
Harrow (NASDAQ:HROW) Stock Falls 6.8% – Here’s Why
Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) dropped 6.8% during trading on Monday. The company traded as low as $31.64 and last traded at $30.8280. Approximately 176,792 shares were traded during trading, a decline of 75% from the average daily volume of 699,208 shares. The stock had previously closed at $33.07. Wall Street
Head-To-Head Contrast: Harrow (NASDAQ:HROW) & Supernus Pharmaceuticals (NASDAQ:SUPN)
Harrow (NASDAQ: HROW - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Insider and Institutional Ownership 72.8% of Harrow shares are
Harrow to Participate in Three Investor Conferences in September
NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following three investor conferences in September in New York, NY: 2026 Cantor Global Healthcare Conference Format: Fireside chat + 1x1 investor meetings Date/Time: Wednesday, September 9, 2026, at 1:35 p.m.
Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half
Ophthalmic disease management company Harrow Inc. (NASDAQ:HROW) on Thursday shared outcomes from a prospective, randomized, contralateral-eye clinical study.
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
Harrow Q2 Earnings Call Highlights
Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half of 2026 with stronger demand across several products, improved pricing and expanded commercial infrastructure.
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
Harrow (HROW) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.24 per share a year ago.
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company.
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ ® / AMELIVU ® ) to reference ranibizumab In treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11 INCHEON, Korea and NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd.
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO® (chloroprocaine HCl ophthalmic gel 3%), a broadly labeled low viscosity ocular anesthetic gel, and BYOOVIZ® (ranibizumab-nuna)i, an FDA-approved biosimilar referencing LUCENTISii (ranibizumab) at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Collectively, the presentations expand the growing body of clinical and real-world evidence supporting Harrow's retina portfolio and reinforce Harrow's commitment to generating quality evidence that strengthens physician confidence, improves patient experience, and supports long-term product adoption and innovation.
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
INCHEON, Korea--(BUSINESS WIRE)-- #Byooviz--Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for commercialization of BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTIS1 (ranibizumab), and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEA2 (aflibercept), upon full transition of commercialization rights from Biogen back to Samsung Bioepis by the end of 20.
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an FDA-approved VKC treatment for pediatric patients.
Price Targets
Harrow initiated with an Outperform at Leerink
$45.00
(was $37.85)
Leerink Partners
Harrow price target lowered to $88 from $91 at Cantor Fitzgerald
$88.00
(was $28.79)
Steve Seedhouse
·
Cantor Fitzgerald
BTIG Reiterates Buy Rating on Harrow Health (HROW) ahead of presentations
$63.00
(was $34.68)
Thomas Shrader
·
BTIG
Harrow Health (HROW) PT Raised to $70 at H.C. Wainwright
$70.00
(was $39.62)
Yi Chen
·
H.C. Wainwright
Cantor Fitzgerald reiterates Overweight rating on Harrow, ups target to $94
$94.00
(was $38.74)
Cantor Fitzgerald
Harrow price target raised to $70 from $42 at Lake Street
$70.00
(was $47.10)
Thomas Flaten
·
Lake Street
Harrow price target raised to $64 from $54 at Craig-Hallum
$64.00
(was $48.93)
Chase Knickerbocker
·
Craig-Hallum
Harrow price target raised to $64 from $60 at H.C. Wainwright
$64.00
(was $34.83)
Yi Chen
·
H.C. Wainwright
Harrow initiated with an Overweight at Cantor Fitzgerald amid path to growth
$76.00
(was $34.93)
Steve Seedhouse
·
Cantor Fitzgerald
Harrow Health (HROW) PT Raised to $73 at B.Riley
$73.00
(was $56.41)
Sahil Kazmi
·
B.Riley Financial
Harrow price target raised to $55 from $45 at Lake Street
$55.00
(was $49.75)
Brooks O'Neil
·
Lake Street
Harrow price target raised to $45 from $30 at Craig-Hallum
$45.00
(was $35.25)
Chase Knickerbocker
·
Craig-Hallum
Harrow price target raised to $30 from $26 at Craig-Hallum
$30.00
(was $19.93)
Chase Knickerbocker
·
Craig-Hallum
Harrow Health (HROW) PT Raised to $25 at Lake Street Capital Markets
$25.00
(was $17.68)
Brooks O'Neil
·
Loop Capital Markets
Harrow price target raised to $25 from $20 at Lake Street
$25.00
(was $18.12)
Brooks O'Neil
·
Lake Street